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Abstract The epidermal growth factor receptor (EGFR) mu-
tant of EGFRvIII is highly expressed in glioma cells, and the
EGFRvIII-specific dendritic cell (DC)-induced tumor antigen-
specific CD8+ cytotoxic T lymphocytes (CTLs) may hold
promise in cancer immunotherapy. Interferon (IFN)-γ-induc-
ible protein (IP)-10 (IP-10) is a potent inhibitor of angiogen-
esis and can recruit CXCR3+ T cells, including CD8+ T cells,
which are important for the control of tumor growth. In this
study, we assessed if the combination of IP10-EGFRvIIIscFv
with DC-induced CTLs would improve the therapeutic anti-
tumor efficacy. IP10-scFv was generated by linking the hu-
man IP-10 gene with the DNA fragment for anti-
EGFRvIIIscFv with a (Gly4Ser)3 flexible linker, purified by
affinity chromatography, and characterized for its anti-
EGFRvIII immunoreactivity and chemotactic activity. DCs
were isolated from human peripheral blood monocyte cells
and pulsed with EGFRvIII-peptide, then co-cultured with
autologous CD8+ T cells. BALB/c-nu mice were inoculated
with human glioma U87-EGFRvIII cells in the brain and
treated intracranially with IP10-scFv and/or intravenously
with DC-induced CTLs for evaluating the therapeutic effect.
Treatment with both IP10-scFv and EGFRvIII peptide-pulsed,
DC-induced CTL synergistically inhibited the growth of gli-
oma and prolonged the survival of tumor-bearing mice, which
was accompanied by the inhibition of tumor angiogenesis and
enhancement of cytotoxicity, thereby increasing the numbers
of brain-infiltrating lymphocytes (BILs) and prolonging the
residence time of CTLs in the tumor.
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Introduction
Malignant gliomas are one of the most devastating tumors
encountered in current clinical practice. Despite improved
surgical management and a multimodal treatment of concom-
itant radiotherapy and chemotherapy followed by adjuvant
chemotherapy with temozolomide (TMZ), the prognosis re-
mains poor, with median overall survival of less than
15 months [1]. Therefore, studies actively focus on testing
new therapeutic approaches, including immunotherapy. The
recognition that lymphocyte infiltration into primary brain
tumors is a favorable prognostic factor for survival has in-
spired a variety of approaches to utilize the immune system for
the treatment of these tumors [2].
Adoptive immunotherapy using antigen-specific CD8+ cy-
totoxic T lymphocytes (CTL) provides a promising approach
for the treatment of cancers and infectious diseases [3]. One
major obstacle to its broad application has been the lack of
reproducible and cost-effective methods for generating clini-
cally relevant numbers of antigen-specific CTLs [4]. The
generation of antitumor-specific T cells ex vivo for adoptive
T cell therapy requires the selection of an appropriate tumor
rejection antigen, a means to present that antigen and condi-
tions that support the generation of antitumor-specific T cells
that are both long-lived and functional. Based on the large
numbers of potential tumor rejection antigens that have been
characterized, the choice of the antigen is not likely to be a
major obstacle [5, 6]. In contrast, the choice of an optimal
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antigen-presenting cell (APC) seems to be much more
challenging.
However, the choice of antigen also appears to be much
more challenging. EGFRvIII is the most prevalent of several
epidermal growth factor receptor (EGFR) mutations found in
human glioma and is expressed in 20–25 % of glioblastoma
(GBM) cases [7]. While EGFRvIII drives enhanced tumori-
genicity through constitutive and unattenuated activation [8],
its expression has not been detected in any normal tissue
examined to date [9], thus making this aberrant receptor a
suitable target for glioma immunotherapy.
Dendritic cells are the most potent professional APCs that
exist in the immune system. Once activated, they process
antigen material and present it on the surface to other immune
cells in the system [10, 11]. For example, dendritic cells (DCs)
can present antigen to initial T lymphocytes and in turn
activate and induce T lymphocytes into antigen-specific
CTLs that target tumor cells [12]. Among the activated
CTLs, CD8+ CTLs are believed to be the major effector cells
that kill target cells [13, 14]. Furthermore, matured DCs can
secrete interleukin-12 (IL-12) and reduce production of
interleukin-10 (IL-10), which inhibits the CD8+ T cell immu-
nologic response [15, 16].
Currently, a number of immunotherapeutic approaches
targeting the unique EGFRvIII antigen are under investiga-
tion. Given the technical difficulty and relatively high cost of
DC-based vaccination therapy, the most promising and prac-
tical active vaccination format to date is a peptide derived
from the novel fusion junction amino acid sequence.
Heimberger et al. [17] demonstrated that immunization of
mice with DCs mixed with a 14-amino-acid peptide,
representing an EGFRvIII fusion sequence, resulted in
prolonged survival of mice with EGFRvIII expressing tumors
as well as long-lasting humoral immunity.
Chemokines are small secreted proteins that activate G
protein-coupled receptors, resulting in the activation of several
distinct signaling cascades and leading, most importantly, to
directed migration of cells along the chemokine gradient [18].
Interferon (IFN)-γ-inducible protein (IP)-10 is a CXC chemo-
kine that is secreted by the endothelium, epithelium, fibro-
blasts, keratinocytes, and monocytes [19, 20]. IP-10 was
initially characterized as a chemoattractant for CXC receptor
(R) 3-expressing T lymphocytes, and it also exerts chemotac-
tic activity for monocytes. However, with the exception of
chemotaxis, IP10 is a potent inhibitor of angiogenesis and
displays some thymus-dependent antitumor effects [21, 22].
Therapy with CXCL10 is effective in reducing the rate of
tumor growth, whereas it fails to induce tumor complete
regression, which suggests that further treatment may require
supplemental combination therapies that directly target tumor
cells.
Antibody-mediated targeting of drugs and genes to specific
cells population has been a long-term research interest in the
field and there has been some success in the targeting of
tumors with antibodies or engineered derivatives [23, 24].
However, the fast clearance of small antibody fragments and
poor penetration of antibodies into the tumor requires multiple
injections and limits their therapeutic potential. The use of
engineered therapeutic single-chain Fv (scFv) fragments that
target tumor cells might overcome this problem. This scFv
was previously well characterized [25, 26] and shown to
specifically target EGFRvIII-expressing U87 glioma cells
in vivo [27].
In this study, we describe the construction of a novel
antibody–chemokine fusion protein, called IP10-
EGFRvIIIscFv, for targeting tumor cells and triggering a
specific immune response against tumors by linking the che-
mokine IP-10 to a scFv fragment specific for EGFRvIII com-
bined with EGFRvIII-specific DCs. It was hypothesized that
IP10-EGFRvIIIscFv would be an effective vehicle for targeted
delivery of cytokines to the sites of the tumor and at the same
time may improve the concentration of DC-induced CTL that
infiltrates into the tumor.
Materials and methods
Cell lines, mice, and healthy volunteers
The U87 human glioblastoma cell line, the U87 line stably
expressing EGFRvIII (U87-MGvIII), human embryonic kid-
ney 293 (HEK-293) cell line, mouse NIH 3 T3 embryonic
fibroblast cell line, and human Hep3B hepatocellular carcino-
ma cell line were obtained from our laboratory. All cell lines
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, Invitrogen) supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, and 10 % fetal bovine serum
(FBS; Invitrogen). Six-week-old female BALB/c-nu mice
(SPF) were obtained from the pathogen-free animal facility
of the Tongji Medical College, Hua Zhong University of
Science and Technology. All mouse procedures and isolation
of peripheral blood mononuclear cells (PBMCs) from five
healthy HLA-A0201 donors were performed in accordance
with institutional protocol guidelines at the Tongji Medical
College. The experimental protocol was established according
to the guidelines of NIH Animal Research and Care and
approved by the Ethics Committee of the Union Hospital of
Tongji Medical College.
Cloning of expression plasmids
The nucleotide sequence encoding human IP-10 complemen-
tary DNA (cDNA) (Gene Bank Accession No. 02530) was
amplified using the following parameters: 22 cycles of dena-
turation at 95 °C for 30 s, primer annealing at 56 °C for 30 s,
and primer extension at 72 °C for 1 min. The following pair of
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primers was used: forward, 5′-TCCGCTCGAGGCCACCAT
GCATCATCATCATCATCATATGAATCAAACTGCCAT
TCTG-3′and reverse, 5′-ATCGGAATTCTCATTTGATTTC
CAGCTTGGTGC-3′. The PCR products were ligated into
the T overhang-cloning site of a TA cloning vector
(Invitogen). The cDNA (Gene Bank Accession No.
U76382.1) encoding EGFRvIIIscFv (MR1) was previously
obtained using a phage display library [25]. We then intro-
duced the sequences encoding a flexible linker of (Gly4Ser)3
and helix-histidine tag (His6-tag), respectively, and sub-cloned
IP10- EGFRvIIIscFv into an XhoI- and EcoRI-digested
GV219 vector (Gene Chem).
Transfections and generation of stable cell lines
We used the conventional lipofectamine method to transfect
NIH3T3 cells. Prior to transfection, NIH3T3 cell lines were
grown at 37 °C and 5%CO2 in DMEMcontaining 10% FBS.
When they reached approximately 70–80 % confluency, vec-
tors were transfected into all systems using the Lipofectamine
TMX reagent (Invitrogen). Briefly, Lipofectamine TMX was
mixed with plasmid DNA (0.68 μg/μl) in Opti-MEMmedium
(Invitrogen) according to the manufacturer’s recommenda-
tions. After culturing the cells for 48 h at 37 °C, the transfected
cells were added to 24-well plates (Costar, USA) at a density
of 1×105 cells/well and selected in 400 μg/ml G418
(Invitrogen). Stable cell lines were obtained in 2–4 weeks
post-transfection. A combination of fluorescent activated cell
sorting (FACS) (FACS Aria, BD Biosciences) and single
colony selection by limiting dilution were used to select for
the highest expressing cells.
Expression and purification of the fusion protein
The chosen highest expressing NIH3T3 cells were grown to
80–90 % and induced with 1–2 μg/ml doxycycline and
10 mM sodium butyrate (Sigma) for 24–36 h. In order to
evaluate the cell surface or intracellular expression of the
fusion protein, cells were harvested by incubating them in
phosphate-buffered saline (PBS) containing 0.5 m MEDTA
andwashedwith PBS containing 0.1% bovine serum albumin
(BSA). For purification, cells with stable expression of the
fusion protein were collected by centrifugation at 300g for
10 min at 4 °C in an Eppendorf high-speed centrifuge. The
cell pellet was then washed three times with PBS and resus-
pended in buffer containing 50 mM HEPES (pH 7.4), 1 mM
EDTA, 1 μM pepstatin, 100 μM leupeptin, and phosphatase
inhibitor cocktail (1:100, Sigma). The cells were sonicated
five times for 10 with 15 s intervals, and the cell lysate was
further centrifuged at 12,000g for 20 min at 4 °C. Supernatant
containing protein was then precipitated with 50 % ammoni-
um sulfate and applied to a Ni-chelating His Trap column
(Amersham-Pharmacia Biotech) equilibrated with PBS (pH
7.4) containing 20 mM imidazole according to the manufac-
turers protocol. The bound protein was eluted with 5 ml of
0.1 M imidazole in PBS followed by dialysis against PBS.
The protein concentration was determined by the BCA kit
(Pierce) according to the manufacturer’s protocol using BSA
as a standard. Fractions collected from the chromatography
steps were analyzed on a 12 % sodium dodecyl sulfate (SDS)
polyacrylamide gel and stained with silver nitrate.
ELISA assay for affinity binding test
The affinity binding of the IP10-scFv purified fusion protein
was measured by ELISA. A 13-amino-acid peptide with a
terminal cysteine (LEEKKGNYVVTDHC) [28] consisting of
an epitope recognized by the anti-EGFRvIIIscFv antibody
was synthesized and cross-linked with OVA as an antigen at
a concentration of 0.5 μg/ml (0.05 μg/well) for coating
ELISA plates. Wells were coated with BSA at a concentration
of 0.5 μg/ml under the same conditions as a negative control.
After overnight incubation at room temperature, the plate was
washed three times with 100 μl of PBS-tween (PBST) and
blocked with a 1 % BSA solution in PBS containing 0.05 %
Tween 20 and finally washed with PBST. Various concentra-
tions (0 to 2 μg/ml) of IP10-scFv were added to individual
wells in triplicate, and the plates were incubated for at least 1 h
at room temperature. After washing, the remaining IP10-scFv
was detected by a biotinylated anti-6×Histagmonoclonal an-
tibody (mAb) and visualized using horseradish peroxidase
(HRP)-conjugated avidin (Peprotech) and substrate of ABTS
(Sigma) by measuring the absorbance at 405 and 650 nm as a
correction wavelength. For analysis, A405nm values after
correction were plotted against the IP10-scFv fusion protein
concentration using Graphpad Prism software. Data were
fitted by nonlinear regression to a hyperbolic function [29]
(A=(Amax c/(KD+c)), where A is the measured signal, Amax is
the signal for saturated binding, and c is the protein concen-
tration. The apparent KD values were determined from this
equation.
Antigen binding assay
U87 cells stably expressing EGFRvIII were washed with PBS
containing 1 % BSA (pH 7.4) and incubated with 100 ng
IP10-scFv fusion protein for 1 h at 4 °C followed by 1 μg/ml
anti-His6mAb. The cells were washed and stained with
fluorescein isothiocyanate (FITC)-conjugated rabbit
antimouse IgG (Abcam) and analyzed by immunofluo-
rescence under a fluorescent microscope or by flow
cytometry. An isotype mAb to lipopolysaccharide
(LPS) and the EGFRvIII negative U87wt cells were
used as the negative controls, respectively.
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In vitro preparation of EGFRvIII peptide CTLs
PBMCs from five healthy HLA-A0201 donors were separated
using Lymphoprep™ Human Lymphocyte density gradient
medium (Axis-Shield). Briefly, the separated mononuclear
cells were cultured in RPMI-1640medium supplementedwith
recombinant granulocyte-macrophage colony stimulating fac-
tor (GM-CSF, 1,000 IU/ml, Peprotech, USA) and recombi-
nant interleukin-4 (IL-4, 500 IU/ml; Peprotech, USA) for
7 days with fresh cytokine medium replaced every 2–3 days.
On day 5, the immature DCs were activated by supplementa-
tion of tumor necrosis factor α (TNF-α, 1,000 IU/ml;
PeproTech) in the culture medium. At the end of cell culture
(day 7), the mature DCs were harvested for subsequent exper-
iments. During the cultivation, DCs were observed by phase-
contrast microscopy and analyzed for surface molecular ex-
pression by flow cytometry (date were not shown).
EGFRvIII peptide-specific CTLs were generated in vitro
according to the method described by Wu et al. [30]. Briefly,
mature DCs were pulsed with EGFRvIII peptides in X-
VIVO15 media for 4 h at 37 °C, then washed twice in
HBSS and irradiated 3,500 rad in a cesium irradiator, and
cultured with autologous purified CD8+ T cells at 1:20 ratio
in 48 well plates. The T cells were individually re-stimulated
with autologous DCs pulsed with the priming peptide every
9 days. Starting on day 12, the T cell cultures were fed with
fresh X-VIVO15 medium containing 50 U/ml of rh-IL-2
(PeproTech) every 3 days. The Elispot assay and CTL assay
were performed 7 days after three rounds of in vitro stimula-
tion with peptide-pulsed DCs.
Cellular migration assays in vitro
Migration assays using the IP10-scFv fusion protein were
performed in a 24-well Transwell chamber (5-μm pore size;
Corning Inc.) coated with 10 mg/ml of fibronectin (Sigma-
Aldrich) on the bottom of the upper chamber. The DC-
induced CTLs were suspended in RPMI 1640 containing
1 % BSA and applied at a density of 1×105/well. Then,
200 μl of the cell suspension was placed into the upper
Transwell chamber and 100 μl (1 ng/μl) aliquots of the
refolded IP10-scFv, 100 ng recombinant human IP-10
(Peprotech), 100 ng anti-EGFRvIII monoclonal antibody
(Zymed), and PBS serially diluted in chemotaxis medium
(RPMI1640 with 1 % BSA) were placed in the lower cham-
ber. The chambers were then incubated for 3 h at 37 °C in a
humid atmosphere of 5 % CO2. After incubation, the number
of cells that migrated to the lower chamber and mixed uni-
formly was determined with crystal violet staining followed
by counting under a light microscope (16 selected high-power
fields). The results are expressed as the chemotaxis index,
which was calculated using the following formula: chemotax-
is index=migration in response to chemokine/migration to
control medium. The index represents the mean of the migra-
tion performed in triplicate.
Tumor challenge
For intracranial (i.c.) tumors, a suspension of 1×107/ml U87-
EGFRvIII cells in 5 μl PBS were stereotactically injected
through an entry site at the bregma located 2 mm to the right
of the sagittal suture and 3 mm below the surface of the skull
of anesthetized mice (6-week-old female mice BABL/C-un,
SPF) using a Reword stereotactic frame (Reword instrument).
We then divided the mice into four groups (n=10 each). One
group of mice received IP10-scFv fusion protein (i.c.) and
EGFRvIII peptide-pulsed, DC-induced CTLs (i.v.) on day 7,
14, and 21 after tumor establishment. Mice in the second
group were only injected with IP10-scFv fusion protein (i.c.)
on the same day time of tumor challenge. The third group
received EGFRvIII peptide-pulsed, DC-induced CTLs (i.v.)
on the same day. Mice in the fourth group were injected with
PBS (i.c.) as a negative control on the same day. However,
mice were monitored carefully for changes in psychosis and
pathologic signs associated with cerebral problems, such as
hemiparesis, loss of appetite, or altered grooming habits. Mice
were euthanized by CO2 to obtain tumor tissues and determine
tumor volumes using Vernier calipers at selected time points
according to the formula: d1×(d2)2×0.5 (d1=largest diame-
ter, d2=perpendicular diameter). Kaplan–Meier survival
curves were prepared and median survival times were deter-
mined for all groups. Survival differences were assessed using
the log-rank Mantel–Cox method.
Cytotoxic assay
The cytotoxic activity of the DC-induced CTLs was deter-
mined using the 51Cr-release assay with minor modifications.
Briefly, the brain-infiltrating lymphocytes (BIL) were isolated
from mice receiving IP10-scFv and DC-induced CTLs, IP10-
scFv, DC-induced CTLs, or PBS on day 14 post-inoculation
as previously described [31]. The BIL (1×105/well) were
stimulated with U87-EGFRvIII cells in 10 % FBS
RPMI1640 for 5 days, and the activated cells were used as
effector cells. In addition, U87-EGFRvIII target cells as well
as HEK-293, Hep3B, and U87-wt cells (1×106) were labeled
with 40μCi51Cr-sodium chromate (Amersham Pharmacia
Biotech) at 37 °C for 2 h. After washing with PBS, the target
cells were incubated in triplicate with activated effectors at
different ratios of 40:1, 20:1, 10:1, and 5:1 in 96-well U-
bottom microtiter plates (Nunc, Roskilde, Denmark) for 4 h,
respectively. The target or effector cells alone were used as the
controls. The target cells were treated with 1 % Triton X-100
and used as the maximum release of 51Cr. The plates were
centrifuged at 600×g, and the supernatant was counted using a
gamma counter. The percentage of glioma-specific
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cytotoxicity was calculated using the following formula:
[[CPM (experimental)−CPM (spontaneous)] / [CPM
(maximum)−CPM (spontaneous)]]×100.
Quantification of tumor vessels and CD8+ T cells
The U87-EGFRvIII tumor tissue sections were permeabilized
using 0.5 % Triton X-100 for 10 min and blocked with 3 %
BSA for 20 min. The rabbit polyclonal antihuman CD31
antibody (ab28364, Abcam) andmousemonoclonal antihuman
CD8 antibody (ab17147, Abcam) was used at 1:50 and1:200
dilutions, respectively, in PBS at 4 °C overnight. The following
day, sections were washed three times with PBS and incubated
subsequently in goat antirabbit Alexa Fluor 594 red fluorescent
(dilution 1:1,000, BD), rabbit antimouse FITC (dilution
1:1,000, BD) for 1 h at room temperature. The sections were
then washed three times with PBS and the number of cells per
high-powered field in several sections from multiple animals
was determined. From these data the mean and standard error
of the mean (SEM) were calculated. The data were subjected to
statistical analysis (one-tailed student’s T-test).
Statistical analysis
Data are expressed as mean±standard deviation (SD). The
difference among different groups was analyzed by one-way
analysis of variance (ANOVA) and post hoc Bonferroni cor-
rection, and the difference between two groups was analyzed
by Student’s t test using SPSS version 16.0 software (SPSS,
USA). The survival of individual groups ofmice was analyzed
by the Kaplan–Meier and log-rank Mantel-Cox methods. A P
value of <0.05 was considered statistically significant.
Results
Construction of the IP10-scFv expression vector
The recombinant expression vector GV219IP10-scFv was
constructed for the production of IP10-scFv fusion protein, in
which the human IP10 gene was linked to the N-terminal of the
anti-EGFRvIII-scFv via a (Gly4Ser)3 flexible linker, which
facilitated both correct folding of the scFv and IP10 proteins
[32, 33]. In addition, a His-tag was introduced at the C-
terminal of IP10-scFv for detection and affinity purification
(Fig 1a). The resultant recombinant protein was expected to be
a fusion protein containing 371 amino acids.
Expression and purification of IP10-scFv fusion protein
The recombinant plasmid GV219IP10-scFv was transfected
into NIH3T3 cells and stable transfectants were selected and
expanded. The recombinant proteins was then purified
from ascites fluids using a Ni-chelating affinity column
and verified by SDS-PAGE and Ag staining. Expression
of the IP10-scFv fusion protein was confirmed in the
transfected NIH3T3 cells, and the apparent molecular
weight of the recombinant protein on SDS-PAGE gel
was approximately 44 kDa (Fig. 1b), which was equiv-
alent to the theoretical value of 47 kDa.
Binding of recombinant IP10-scFv to EGFRvIII
The binding properties of the recombinant IP10-scFv were
analyzed by ELISA. The EGFRvIII was coated onto an
ELISA microplate, and the IP10-scFv protein bound to it
was detected with a monoclonal antibody against 6×His-tag.
IP10-scFv was capable of binding to EGFRvIII in a dose-
dependent manner with saturation at IP10-scFv protein con-
centrations greater than 450 nM. The apparent dissociation
constant (KD) was found to be 1.02±0.06×10
−8 M. However,
strong signals were obtained at the lowest IP10-scFv concen-
trations tested in the assay, which complicated quantitative
evaluation of the data.
Antigen binding of IP10-scFv fusion protein
To determine the ability of recombinant IP10-scFv binding to
EGFRvIII, the binding of IP10-scFv, IgG to U87-EGFRvIII
cells, and U87wt cells were analyzed by immunofluorescence
under a fluorescent microscope or by flow cytometry analysis.
The results showed that only IP10-scFv bound specifically to
the surface of U87- EGFRvIII cells, while no binding was
detected from either the IgG control or IP10-scFv incubated
withU87wt cells (Fig. 2).
CTL migration in response to IP10-scFv
To determine whether the IP10-scFv fusion protein could
facilitate the transendothelial chemotaxis required for recruit-
ment of CTL to the target cells, we preparedDC-inducedCTLs
in vitro. The chemotactic activity of IP10-scFv was then tested
for the migration of CTLs in the transwell migration assays. As
shown in Fig 3, the chemotactic activities of IP10-scFv were
similar to that of recombinant human IP10 (P>0.05).
Importantly, there was no detectable chemotactic activity for
the anti-EGFRvIII mAb or PBS controls. Collectively, these
data clearly indicate that the purified recombinant IP10-scFv
protein retains immunoreactivity of the scFv against the
EGFRvIII mAb and the chemotactic activity of IP10.
Antitumor efficacy of the combination of EGFRvIII
peptide-pulsed, DC-induced CTLs and IP10-scFv
We next examined the efficacy of the IP10-scFv together with
EGFRvIII peptide-pulsed, DC-induced CTLs in a murine
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intracerebral glioma model. In the present study, BABL/c nu
mice received adoptive immunotherapy by injecting
EGFRvIII peptide-pulsed, DC-induced CTLs (i.v.) and IP10-
scFv (i.c.) beginning 7 days after tumor implantation. Control
groups were only injectedwith IP10-scFv (i.c.), CTLs (i.v.), or
PBS (i.c.), respectively. Vaccinations were repeated every
7 days for a total of three doses. Kaplan–Meier survival plots
were drawn, and median survival times were determined for
all groups. We found that the tumor volumes of each group
expanded at a near-linear rate as determined by measuring
their size every 7 days (Fig. 4a). In contrast, the rate of tumor
growth in animals treated with DC-induced CTLs alone or
IP10-scFv fusion protein alone was significantly decreased
compared to the PBS control-treated animals (P<0.01, both
comparisons). In addition, the combination treatment of DC-
induced CTLs plus IP10-scFv reduced the tumor growth more
effectively than DC-induced CTLs or IP10-scFv alone
(P<0.01, both comparisons). Similarly, we monitored the
overall survival of tumor-bearing mice and found that while
all of the mice treated with PBS or DC-induced CTLs alone
died between day 33 and 52 post-inoculation, less than 50 %
of the mice that had been treated with IP10-scFv or with both
IP10-scFv and DC-induced CTLs had died by day 65 post-
inoculation (Fig. 4b). Moreover, we found that 10 and 50% of
Fig. 1 Generation and characterization of recombinant IP10-scFv. aThe
IP10-scFv gene was inserted into GV219 under the control of the PCMV
promoter as a XholI/EcoRI fragment and amplified from the plasmid
GV219IP10-scFv. b The expressed IP10-scFv was expected to be a
fusion protein of 371 amino acids with a molecular weight of 44 kDa,
which contains a His-tag at the C-terminus for detection and purification.
The purified protein was then subjected to 12 % SDS-PAGE and stained
with Ag. Lane M, mid-range protein molecular weight markers (kDa).
Lane 1, the purified IP10-scFv fusion protein. Lane 2, BSA
Fig. 2 Antigen binding of the
refolded IP10-scFv to EGFRvIII.
U87-EGFRvIII cells were
incubated separately with IP10-
scFv (a) or IgG (b) followed by
anti-His6 mAb incubation. U87wt
cells were incubated with IP10-
scFv as a control group (c). The
percentage of refolded IP10-scFv
bound to U87-EGFRvIII by flow
cytometry analysis (d) was71.3 %
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mice survived for the entire observation period (up to 100 days
post-inoculation) in the groups treated with IP10-scFv and
IP10-scFv/DC-induced CTLs, respectively. The effect of
treatment with IP10-scFv and DC-induced CTLs on
prolonging the survival of tumor-bearing mice was signifi-
cantly greater than that of treatment with DC-induced CTLs
alone (P<0.001) or with IP10-scFv alone (P<0.05).
Therefore, treatment with both IP10-scFv and DC-induced
CTLs synergistically inhibited the growth of implanted glio-
ma in vivo and prolonged the survival of tumor-bearing mice.
Cytotoxicity of CTLs in mice
We next demonstrated tumor-specific CTLs against U87-
EGFRvIII cells with a standard 4h51Cr release assay using
BIL from the four treated groups, As shown in Fig 5a, there
was a low level of cytotoxicity in the mice that had been
treated with IP10-scFv alone, which was similar to that in
the control mice, regardless of the ratios of effectors to targets.
In contrast, the percentages of U87-EGFRvIII lysed by the
BILs from mice treated with EGFRvIII peptide-pulsed, DC-
induced CTLs increased significantly as the ratio of effectors
to targets increased (P<0.05–0.001), and the frequency of
U87-EGFRvIII cells lysed by the BILs frommice treated with
IP10-scFv/CTLs was significantly higher (P<0.01).
Similarly, the in vitro generated CTLs had potent cytotoxicity
against glioma cells, but failed to kill other tumor cells and
non-tumor cells (Fig. 5b).
Effect of IP10-scFv+EGFRvIII peptide-pulsed, DC-induced
CTLs on tumor vessel and CD8+ T cell counts
Immunofluorescence studies were performed on intracere-
bral U87-EGFRvIII tumors from mice vaccinated with four
treatments (IP10-scFv/EGFRvIII peptide-pulsed, DC-
induced CTLs, IP10-scFv, EGFRvIII peptide-pulsed, DC-
Fig. 3 The chemotactic activity
of the purified IP10-scFv to
EGFRvIII peptide-pulsed, DC-
induced CTLs. a 100 ng refolded
fusion protein IP10-scFv, b
100 ng recombinant human IP10,
c 100 ng anti-EGFRvIII
monoclonal antibody, or d PBS.
e Data were expressed as the
chemotaxis index of two groups
of CTL cells from three separate
experiments. There was no
difference between IP10-scFv and




significantly higher in the IP10-
scFv or hIP-10 groups than the
PBS or anti-EGFRvIII mAb
groups (P<0.001)
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induced CTLs, or PBS). As shown in Fig 6a, CD31 staining
was used to detect vessels in U87-EGFRvIII tumors and
showed a significant decrease in the number of tumor
vessels in mice treated with IP10-scFv/EGFRvIII peptide-
pulsed, DC-induced CTLs or IP10-scFv compared to those
in the control group (P<0.01). However, there were no
significant difference in the number of tumor vessels in
mice treated with IP10-scFv/EGFRvIII peptide-pulsed,
DC-induced CTLs and IP10-scFv (P>0.05). In addition, a
large number of CD8+ T cells was identified in the intrace-
rebral tumors of mice vaccinated with IP10-scFv/EGFRvIII
peptide-pulsed, DC-induced CTLs (P<0.001). In contrast,
there was no significant increase in the number of CD8+ T
cells in the intracerebral tumors from mice treated with
IP10-scFv or PBS (P>0.05). These results verified the
limited number of CTLs in vivo, especially activated
CD8+ T cells under normal circumstances.
Discussion
Adoptive immunotherapy using tumor-reactive T lympho-
cytes has emerged as a powerful approach for the treatment
of bulky, refractory cancer [34, 35]. DC-based vaccination to
activate T cells, which is one main form of adoptive immuno-
therapy, has been shown to effectively mediate antitumor
immunity [36]. DC-based immunotherapy can be approached
in one of two ways: direct immunization with antigen (tumor-
associated proteins, peptides, or tumor lysates) pulsed DCs or
adoptive transfer of in vitro expanded CTLs following stimu-
lations with antigen-pulsed DCs. A broad range of immuno-
logical defects have been documented in glioma patients,
including decreased T cell numbers, impaired T cell respon-
siveness, and defective signaling after T cell receptor TCR/
CD3 stimulation [37]. However, tumor-specific CD8-positive
CTLs constitute the most important effector cells for antitu-
mor responses [38, 39]. It has been previously shown that
in vitro specific CTLs can be generated using peptide-pulsed
autologous DC [40, 41]. However, the interactions between
DCs and T lymphocytes are very complicated and may in-
volve different mechanisms [42, 43].
Fig. 4 Inhibition of tumor growth and survival analysis. a. The kinetics
of tumor growth. Data are expressed as mean±standard deviation (SD) of
the tumor volumes of each group of mice (n=10 per group per time
point). b. The survival curves of tumor-bearing mice were estimated
using the Kaplan–Meier method. Data are expressed as the mean
percentage of each group of mice (n=10 per group) that survived
throughout the period. *P<0.05, **P<0.01 vs. the PBS group;
#P<0.05, ##P<0.01 vs. the EGFRvIII peptide-pulsed, DC-induced CTL
group; ^P<0.05, ^^P<0.01 vs. the IP10-scFv group
Fig. 5 The glioma-specific cytotoxicity. a The BIL were isolated from
the IP10-scFv/EGFRvIII peptide-pulsed, DC-induced CTLs, IP10-scFv,
EGFRvIII peptide-pulsed, DC-induced CTLs, or PBS-treated mice on
day 14 post-inoculation. b The BIL (1×105/well) were stimulated with
U87wt, HEK293, Hep3B, and U87-EGFRvIII cells in vitro for 5 days.
Data are expressed as mean±SD of the percentages of glioma-specific
cytotoxicity in different groups of mice from three separate experiments.
*P<0.05, **P<0.01 vs. the PBS and U87wt groups; #P<0.05, ##P<0.01
vs. the IP10-scFv and HEK293 groups; ^P<0.05, ^^P<0.01 vs. the
EGFRvIII peptide-pulsed, DC-induced CTLs and Hep3B groups
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In general, the induction of T lymphocyte activation, pro-
liferation, and function not only requires recognition between
the Tcell receptor (TCR) and specific major histocomptability
complex (MHC) peptide complexes expressed on the surface
of APCs (such as DCs and tumor cells), but also the interac-
tion between co-stimulatory molecules on T cells and APCs
[44]. Nevertheless, the recognition between the TCR of T
lymphocytes and antigen presented by DCs is limited by
MHC molecules, and therefore, the killing of target cells by
activated CTLs is also limited by MHC molecules. Wu et al.
[30] first reported that human DCs pulsed with a 9-mer
peptide containing the amino acid fusion site of EGFRvIII
protein effectively induced autologous EGFRvIII peptide-
specific CTLs in vitro, and that these CTLs effectively killed
EGFRvIII-expressing human glioma cells. This 9-mer
EGFRvIII peptide is also presented on HLA-A2 molecules,
and therefore, the killing of EGFRvIII-expressing glioma cells
by peptide-specific CTLs is HLA-A2-restricted. Our findings
confirmed the previous work ofWu et al. by finding that the 9-
mer EGFRvIII-specific peptide on antigen-pulsed DCs can
indeed induces tumor-specific CTLs in vitro.
To date, several strategies have been assessed for creating
DC-based cancer vaccines, including: (1) loading DCs with
defined TAAs, which is the most commonly applicable strat-
egy, for DC-based vaccination, but has a number of draw-
backs [45]; (2) pulsing DCs with tumor DNA/RNA; and (3)
generating fusions of DCs and tumor cells. DC/glioma-
specific peptides have been confirmed to be a useful strategy
to elicit CTL responses and have been shown to be more
effective than other types of DC-based vaccines. Therefore,
EGFRvIII peptide-pulsed DCs have distinct advantages over
other types of DCs, which provide a robust platform for the
generation of large numbers of functional antigen-specific
CD8+ T cells [46]. We found that these CTLs effectively
killed EGFRvIII-expressing human glioma cells. Therefore,
future investigations will focus on the potential use of
EGFRvIII peptide in DC-based immunotherapy in clinical
research.
Nevertheless, efficient immunotherapy requires that cyto-
toxic T cells not only persist in vivo, but also migrate to and
function optimally at the tumor site. The antitumor activity of
EGFRvIII peptide-pulsed, DC-induced CTLs is limited
in vivo because of tumor immunologic escape [47] and the
immunogenicity of tumor deficiency [48]. Although we
injected tumor-specific CTLs into the center of the tumor, it
is difficult for the cells to infiltrate throughout the tumor from
the injection site because of the tumor microenvironment [49],
which can inhibit the antitumor activity of CTLs and surround
the tumor.
Notably, IP-10 has been shown to be a potent chemotac-
tic factor of CTL [50], and a scFv is an attractive carrier of
bioactive molecules into the tumor tissues due to its antigen
specificity and small size [51]. Interestingly, IP10 is re-
quired for CNS glioma homing as well as the induction of
effector CTLs because its receptor, CXCR3, is highly
expressed on active T cells. In this study, we tested whether
local treatment with IP-10 could effectively EGFRvIII
peptide-pulsed, DC-induced CTLs into the tumor and in-
hibit the growth of glioma in mice. We first constructed the
fusion gene IP10-scFv that specifically recognized glioma-
specific EGFRvIII antigen, which is commonly expressed
on the membrane surface of glioma cells, and effectively
recruited glioma-specific CTLs into the tumor to inhibit
tumor growth in mice [27]. Following purification and
refolding, we found that the recombinant fusion protein
IP10-scFv had similar affinity to that of scFv and retained
the immunoreactivity of scFv and the chemotactic activity
of IP-10. Our results indicate that large numbers of CD8+ T
cells infiltrate tumors after antigen-specific T cell transfer
following stimulation with EGFRvIII peptide-pulsed DCs.
Although this approach was effective in an animal model,
the delivery method limits its use in the clinic. Therefore, in
future studies we will improve the method of delivery for
humans.
Fig. 6 Immunofluorescent staining of CD31 and CD8 in tumor tissue of
mice. a Quantification of CD31 expression in each group. In the IP10-
scFv+EGFRvIII peptide-pulsed DC-induced CTL group, the number of
vessels was the lowest and was not different than theIP10-scFv group
(P>0.05). However, the number of CD31-positive vessels was the
highest in the PBS group. b Quantification of CD8 expression in each
group. The IP10-scFv/EGFRvIII peptide-pulsed, DC-induced CTLs can
attract the most CD8+Tcells to infiltrate the tumor. In contrast, there were
no obvious differences in the number of CD8+ T cells between the PBS
and IP10-scFv-treated groups. Data are expressed as mean±SD of the
percentages of CD31 and CD8 in different groups of mice from three
separate experiments. *P<0.05, **P<0.01 vs. the PBS group; #P<0.05,
##P<0.01 vs. the EGFRvIII peptide-pulsed DC-induced CTL group;
^P<0.05, ^^P<0.01 vs. the IP10-scFv group
Tumor Biol. (2014) 35:7781–7791 7789
Conclusion
In summary, our data indicated that treatment with IP10-scFv
or EGFRvIII peptide-pulsed, DC-induced CTLs significantly
enhanced cell infiltration in the brain and expanded the effec-
tor T cells in a specific immune response, which was accom-
panied by enhanced CD8+ T cell-mediated cytotoxicity in the
brain. In addition, treatment with both IP10-scFv and
EGFRvIII peptide-pulsed, DC-induced CTLs synergistically
enhanced the therapeutic effect of inhibiting the growth of
glioma and prolonged the survival of tumor-bearing mice.
Therefore, our findings may provide new insight in glioma-
specific immunity and aid in the design of new immunother-
apies for treating glioma.
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